Pharmaceutical preparation
Pharmaceutical preparations include at least one component that enhances sexual response and at least one other compound that enhances sexual sensitivity and pleasure. The component that enhances sexual response enhances blood flow to the genital region. Examples include compounds that dilate blood vessels, such as compounds that increase the amount of nitric oxide (NO) in the blood. The component that enhances sexual sensitivity and pleasure includes one or more cannabinoid compounds from the plant genus Cannabis . Examples include tetrahydrocannabinol (THC), the main psychoactive constituent of Cannabis , and cannabidiol (CBD), which is less or non-psychoactive and modulates THC activity. The ratio of THC/CBD can be selected depending on age, gender, physical health, and/or psychological condition of the user.
1. A tablet or capsule for enhancing sexual response and sensitivity in a human, consisting essentially of:
a cannabis extract consisting essentially of about 50 mg to about 500 mg of tetrahydrocannabinol (THC) and about 10 mg to about 250 mg of cannabidiol (CBD); and a pharmaceutically effective amount of a component selected from the group consisting of sildenafil, tadalafil, and vardenafil.
2. The tablet or capsule of claim 1 , wherein the cannabis extract contains at least one of cannabinol (CBN), tetrahydrocannabivarin (THCV), cannabigerol (CBG), dronabinol, nabilone, a derivative of THC, or a derivative of CBD.
3. The tablet or capsule of claim 1 , wherein the cannabis extract is obtained from plant parts of one or more plants selected from Cannabis sativa, Cannabis indica , and hybrids thereof.
4. The tablet or capsule of claim 1 , wherein the tablet or capsule contains about 75 mg to about 400 mg of THC.
5. The tablet or capsule of claim 1 , wherein the tablet or capsule contains about 100 mg to about 300 mg of THC.
6. The tablet or capsule of claim 1 , wherein the tablet or capsule contains about 75 mg to about 400 mg of THC and about 15 mg to about 200 mg of CBD.
7. The tablet or capsule of claim 1 , wherein the tablet or capsule contains ratio of THC to CDB of at least about 2:1 THC/CBD.
8. The tablet or capsule of claim 7 , wherein the ratio of THC to CDB is in a range of about 3:1 to about 20:1 THC/CBD.
9. The tablet or capsule of claim 7 , wherein the ratio of THC to CDB is in a range of about 4:1 to about 15:1 THC/CBD.
10. The tablet or capsule of claim 1 , wherein the tablet or capsule consists essentially of the cannabis extract and vardenafil.
11. A tablet or capsule for enhancing sexual response and sensitivity in a human, consisting essentially of:
a cannabis extract consisting essentially of about 50 mg to about 500 mg of tetrahydrocannabinol (THC) and about 10 mg to about 250 mg of cannabidiol (CBD); and
a pharmaceutically effective amount of sildenafil.
12. The tablet or capsule of claim 11 , wherein the cannabis extract contains at least one of cannabinol (CBN), tetrahydrocannabivarin (THCV), cannabigerol (CBG), dronabinol, nabilone, a derivative of THC, or a derivative of CBD.
13. The tablet or capsule of claim 11 , wherein the tablet or capsule has a ratio of THC to CDB in a range of about 2:1 to about 25:1 THC/CBD.
14. The tablet or capsule of claim 13 , wherein the ratio of THC to CDB is in a range of about 3:1 to about 20:1 THC/CBD.
15. The tablet or capsule of claim 13 , wherein the ratio of THC to CDB is in a range of about 4:1 to about 15:1 THC/CBD.
16. A tablet or capsule for enhancing sexual response and sensitivity in a human, consisting essentially of:
a cannabis extract consisting essentially of about 50 mg to about 500 mg of tetrahydrocannabinol (THC) and about 10 mg to about 250 mg of cannabidiol (CBD); and
a pharmaceutically effective amount of tadalafil.
17. The tablet or capsule of claim 16 , wherein the cannabis extract contains at least one of cannabinol (CBN), tetrahydrocannabivarin (THCV), cannabigerol (CBG), dronabinol, nabilone, a derivative of THC, or a derivative of CBD.
18. The tablet or capsule of claim 16 , wherein the tablet or capsule has a ratio of THC to CDB in a range of about 2:1 to about 25:1 THC/CBD.
19. The tablet or capsule of claim 18 , wherein the ratio of THC to CDB is in a range of about 3:1 to about 20:1 THC/CBD.
20. The tablet or capsule of claim 18 , wherein the ratio of THC to CDB is in a range of about 4:1 to about 15:1 THC/CBD.